Document Detail

Management of hypertension in chronic heart failure.
MedLine Citation:
PMID:  19379066     Owner:  NLM     Status:  MEDLINE    
Chronic heart failure (CHF) is associated with frequent hospitalizations and high mortality. It affects more than 5 million individuals in the USA, and another 660,000 new cases are diagnosed each year; overall, heart failure (HF) now accounts for 7% of all deaths from cardiovascular disease. Hypertension (HTN) increases the risk of development of HF and it precedes it in 75% of cases. HF patients are nearly evenly divided between those with reduced left ventricular (LV) function or systolic dysfunction and those with preserved LV systolic function or diastolic dysfunction. The management of HTN in patients with CHF is challenging. Drugs such as beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone receptor blockers, hydralazine and nitrates, which have shown mortality benefit in CHF and exert antihypertensive effects, should be used as first-line agents to control HTN in CHF. In addition, antihypertensive drugs such as alpha-receptor blockers that can increase mortality in HF should be avoided. The dihydropyridine group of calcium channel blockers are good antihypertensive medications with a neutral effect on mortality in patients with CHF. These may be used in CHF patients with refractory HTN. In patients with HF with reduced ejection fraction, HTN is treated differently in comparison to patients with HF with normal ejection fraction. This article reviews the treatment of essential HTN in patients at risk for developing HF, in the presence of HF and the latest developments in treatment that might benefit both HTN and HF management.
Saraswathy Manickavasagam; Ramanna Merla; Michael M Koerner; Ken Fujise; Sanjay Kunapuli; Salvatore Rosanio; Alejandro Barbagelata
Related Documents :
12870536 - Clinical and therapeutical follow-up of hiv-associated pulmonary hypertension: prospect...
9323096 - Sera from chronic chagasic patients with complex cardiac arrhythmias depress electrogen...
17394896 - The new heart failure guidelines: strategies for implementation.
12473986 - One year temporal pattern of neurohumoral factors and natriuretic peptides compared wit...
22595356 - The role of cardiac disease parameters in predicting the results of holter monitoring i...
20861646 - Serum il-9 levels depend on allergen exposure: preliminary study.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  7     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-04-21     Completed Date:  2009-07-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  423-33     Citation Subset:  IM    
University of Texas Medical Branch, 301 University Boulevard 5,106 John Sealy Annex, Galveston, TX 77555-0553, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / pharmacology,  therapeutic use*
Blood Pressure / drug effects
Chronic Disease
Heart Failure / drug therapy*,  etiology,  mortality
Hypertension / complications,  drug therapy*,  mortality
Risk Factors
United States / epidemiology
Ventricular Dysfunction, Left / complications,  drug therapy
Reg. No./Substance:
0/Antihypertensive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of gender in patients with acute coronary syndrome.
Next Document:  Modern imaging of the infarct core and the ischemic penumbra in acute stroke patients: CT versus MRI...